(TORONTO, Sept. 27, 2021) — Amacathera Inc. has been named a Canadian Innovation Exchange (CIX)’s Top 20 Early company for 2021.
The awards, part of the CIX Digital Summit, recognize Canada’s most innovative technology companies at both the early and growth-stage. The CIX TOP 20 Early category recognizes companies with net revenue of less than CAD $5 million and/or who have raised less than $10 million. In 2021, the program received 492 applications.
“We’re proud to be named a CIX Top 20 early company,” said Dr. Mike Cooke, CEO and co-founder. “AmacaThera has had a landmark year in 2021, closing an oversubscribed $10.3M Series A and receiving Health Canada’s approval to advance our lead product, AMT-143, to Phase I clinical trials. The team has also worked hard to adapt to the ongoing challenges presented by the pandemic and are making great strides in refining our manufacturing processes.”
Co-founded in 2016 by Dr. Molly Shoichet and Dr. Mike Cooke, AmacaThera was spun out of Shoichet’s University of Toronto laboratory through the UTEST accelerator to commercialize novel hydrogels. The company’s lead product, AMT-143, aims to improve post-operative pain management with potential applicability to any surgical incision.
The company’s investors include Lumira Ventures, Viva BioInnovator, Sprout BioVentures, BDC Capital Women in Technology (WIT) Venture fund, Inveready, MBX Capital, CR Capital Management, StandUp Ventures and MaRS IAF.
#
About AmacaThera Inc.
AmacaThera is a clinical-stage biotechnology company developing a novel drug delivery platform to improve patient outcomes across multiple therapeutic areas, including post‑surgical pain management, cancer, and other hard‑to‑reach target areas.
About the Canadian Innovation Exchange (CIX)
CIX is an annual curation program and internationally recognized conference that showcases Canada’s most promising early-stage and scaling startups. Now in its 14th year, CIX-invited delegates include North American VCs, corporations, private equity investors and advisors. CIX is Canada’s largest tech startup investment conference.
AmacaThera, a leader in the development of novel injectable, localized therapeutics based upon its AmacaGel delivery platform, announced the closing of a CAD$4.0 million financing round.Read more
AmacaThera collaborates with University Health Network to evaluate the economic impact of post-surgical opioid use. They are developing non-opioid analgesic, AMT-143, aiming to reduce the reliance on opioid medications.Read more
AmacaThera Inc today announced that the first subjects have been dosed in the company's Phase 1 first-in-human clinical investigation of the safety of AmacaGel™.Read more